The combination of motixafortide, KEYTRUDA® and chemotherapy met all trial endpoints, including increasing overall and progression free survival.
List view / Grid view
Filter the results
The EMA's human medicines committee has released its results for the December meeting, suggesting which therapies should receive marketing authorisation.
Novartis, Merck and Allergan have joined numerous other pharmaceutical companies by increasing the price of certain drugs since the start of 2020.